RP2 with nivolumab for untreated uveal melanoma
Treatments studied
Part of Cancer, Eyes & vision, Skin clinical trials.
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have uveal melanoma that has spread (metastatic) and cannot be fully removed with surgery.
- You have at least one tumor that is at least 1 cm (about the size of a pea) that can be injected directly with the study drug.
- You are willing to give a small sample of your tumor (biopsy) for testing.
- You have not had any immunotherapy (checkpoint inhibitors) since your uveal melanoma diagnosis.
- You do not have active infections like hepatitis B, C, HIV, or serious herpes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests a new kind of virus-based treatment (RP1) given directly into melanoma tumors to see if it can reduce the chance of cancer spreading to nearby lymph nodes. It's for people with thicker or more advanced skin melanoma that still has visible tumor or positive margins after biopsy.
This trial tests a combination of two drugs, RP2 (an oncolytic virus injected into tumors) and tivozanib (a daily pill), for people with advanced kidney cancer that has clear-cell or sarcomatoid features and has grown after prior immunotherapy and a targeted therapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests whether adding a liver-directed therapy (PHP) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) works better than the immunotherapy drugs alone for people whose uveal melanoma has spread to the liver.
This trial tests a new drug, RBP-01, given before either surgery to remove the eye or radiation therapy, to see if it can help treat a type of eye cancer called uveal melanoma. It may offer a new option for people with larger tumors or those at risk of vision loss from standard treatment.
Hear when a new Metastatic Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.